Current and historical daily PE Ratio for Novacyt (
LSE:NCYT
) from 2017 to Apr 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Novacyt stock (LSE:NCYT) PE ratio as of Apr 24 2024 is 0.
More Details
Novacyt SA (LSE:NCYT) PE Ratio (TTM) Chart
Novacyt SA (LSE:NCYT) PE Ratio (TTM) Historical Data
View and export this data going back to 2017. Start your Free Trial
Total 1238
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Novacyt PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-25 | At Loss | 2024-02-19 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-05 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
| 2024-04-03 | At Loss | 2024-01-29 | At Loss |
| 2024-04-02 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
| 2024-03-20 | At Loss | 2024-01-17 | At Loss |
| 2024-03-19 | At Loss | 2024-01-16 | At Loss |
| 2024-03-18 | At Loss | 2024-01-15 | At Loss |
| 2024-03-15 | At Loss | 2024-01-12 | At Loss |
| 2024-03-14 | At Loss | 2024-01-11 | At Loss |
| 2024-03-13 | At Loss | 2024-01-10 | At Loss |
| 2024-03-12 | At Loss | 2024-01-09 | At Loss |
| 2024-03-11 | At Loss | 2024-01-08 | At Loss |
| 2024-03-08 | At Loss | 2024-01-05 | At Loss |
| 2024-03-07 | At Loss | 2024-01-04 | At Loss |
| 2024-03-06 | At Loss | 2024-01-03 | At Loss |
| 2024-03-05 | At Loss | 2024-01-02 | At Loss |
| 2024-03-04 | At Loss | 2023-12-29 | At Loss |
| 2024-03-01 | At Loss | 2023-12-28 | At Loss |
| 2024-02-29 | At Loss | 2023-12-27 | At Loss |
| 2024-02-28 | At Loss | 2023-12-22 | At Loss |
| 2024-02-27 | At Loss | 2023-12-21 | At Loss |
| 2024-02-26 | At Loss | 2023-12-20 | At Loss |
| 2024-02-23 | At Loss | 2023-12-19 | At Loss |
| 2024-02-22 | At Loss | 2023-12-18 | At Loss |
| 2024-02-21 | At Loss | 2023-12-15 | At Loss |
| 2024-02-20 | At Loss | 2023-12-14 | At Loss |
Novacyt SA (LSE:NCYT) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Novacyt SA
NAICS : 325413
ISIN : FR0010397232
Compare
Compare
Traded in other countries / regions
ALNOV.FranceNCYT.UKNVYTF.USANYZ.Germany IPO Date
2017-11-01Description
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers